Polymyositis - Epidemiology Forecast - 2034

Key Highlights

• In 2023, the prevalence of Polymyositis was highest in the US among the 7MM, accounting for nearly 37 thousand cases which are further expected to increase by 2034.
• In the United States, in 2023, ~14 thousand males and ~23 thousand females were affected with Polymyositis.
• In 2023, Germany had the highest Polymyositis-diagnosed prevalence among EU4 and the UK, with 9,333 cases, followed by France and the UK. In contrast, Spain reported the lowest diagnosed prevalence of polymyositis in the European region in the same year. As per the analyst's analysis, diagnosed prevalence in EU4 and the UK is expected to increase at a CAGR of 2.21% by 2034.
• As per the analyst's estimates, Japan accounted for nearly 16% of the Total Diagnosed Prevalent Cases of Polymyositis in the 7MM in 2023.
• Epidemiological studies of Polymyositis are challenged by its rarity and overlap with other autoimmune disorders, leading to diagnostic difficulties and potential underreporting. The lack of standardized criteria and limited understanding of genetic and environmental factor further complicate accurate prevalence estimates.

This report delivers an in-depth understanding of Polymyositis, historical and forecasted epidemiology of Polymyositis in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034

Polymyositis Disease Understanding

Polymyositis Overview

Polymyositis is a disorder of inflammatory myopathies characterized pathologically by the presence of inflammatory infiltrates in striated muscle. The foremost clinical manifestation of polymyositis is proximal muscle weakness. The etiology of polymyositis is unknown, but current evidence suggests that it is an autoimmune disorder. The prevalence of idiopathic inflammatory myopathies (IIMs) is fairly low as reported by different research. Polymyositis is rare in childhood and presents mainly after the second decade of life, and the most common time of presentation is between 45 and 60 years of age. Polymyositis can affect people of all ages but most commonly presents between 50 and 70 years. Polymyositis is rarely seen in people younger than 18 and is twice as common among females as males. The classic symptom of polymyositis is proximal weakness, which may manifest as difficulty holding arms over the head, climbing stairs, or rising from a chair. Weakness of the striated muscle of the upper esophagus may result in dysphagia, dysphonia, and aspiration. The chest wall muscles may be affected, leading to ventilator compromises.

Polymyositis Diagnosis

Polymyositis is an inflammatory muscle disease characterized by progressive muscle weakness, typically affecting the proximal muscles, such as those in the hips, thighs, and shoulders. Diagnosis involves a combination of clinical evaluation, laboratory tests, and imaging. Key indicators include elevated levels of muscle enzymes like creatine kinase, abnormal electromyography (EMG) results, and characteristic findings on muscle biopsy showing inflammatory infiltrates and muscle fiber damage. MRI can help identify affected muscles. Differential diagnosis is crucial to rule out other conditions with similar symptoms. Prompt diagnosis is essential for effective management and treatment to prevent muscle damage.

Polymyositis Epidemiology

For the purpose of designing the patient-based model for the Polymyositis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by, Total Diagnosed Prevalent Cases of Polymyositis, Gender-specific Diagnosed Prevalent Cases of Polymyositis, and Age-specific Diagnosed Prevalent Cases of Polymyositis in the 7MM covering, the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2020 to 2034.

• In the assessment, the estimated total diagnosed prevalent cases of Polymyositis in the 7MM were nearly 80 thousand in 2023.
• Among the European countries, Germany had the highest diagnosed prevalent cases of Polymyositis with ~9 thousand cases, followed by France, which had diagnosed prevalent population of ~7 thousand in 2023. On the other hand, Spain had the lowest prevalent population (3 thousand cases).
• Japan had nearly 12 thousand total diagnosed prevalent cases of Polymyositis in 2023, accounting for approximately 16% in 7MM.
• The analysis indicates that in Japan, females were more affected than males, with approximately 9 thousand female cases and 3 thousand male cases in 2023.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease prevalence.

The analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the Stanford University School of Medicine, Northwestern University Feinberg School of Medicine, University of California, San Francisco, US; University of Milan, Italy; Hospital Universitario La Paz, Spain; Pitié-Salpêtrière Hospital, Paris; Royal Liverpool University Hospital, Osaka University Hospital and Kyoto University Hospital, Japan;; and others were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Scope of the Report

• The report covers a segment of key events, an executive summary, descriptive overview of Polymyositis, explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.
• The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Polymyositis Report Insights

• Patient Population
• Country-wise Epidemiology Distribution
• Total Diagnosed Prevalent Cases of Polymyositis
• Gender-specific Diagnosed Prevalent Cases of Polymyositis
• Age-specific Diagnosed Prevalent Cases of Polymyositis

Polymyositis Report Key Strengths

• 11 years Forecast
• The 7MM Coverage
• Polymyositis Epidemiology Segmentation

Polymyositis Report Assessment

• Current Diagnostic Practices Patient Segmentation

Epidemiology Insights

• What are the disease risk, burdens, and unmet needs of Polymyositis? What will be the growth opportunities across the 7MM concerning the patient population of Polymyositis?
• What is the historical and forecasted Polymyositis patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• Why is the diagnosed prevalent cases of Polymyositis in Japan lower than the US?
• Which country has a high patient share for Polymyositis?

Reasons to Buy

• Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the Polymyositis prevalence cases in varying geographies over the coming years.
• A detailed overview of Gender and Age Grade-specific diagnosed prevalence of Polymyositis, along with diagnosed prevalence of Polymyositis Based on severity of airflow limitation and diagnosed prevalence of Polymyositis based on symptoms and exacerbation history.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Frequently Asked Questions

1. What is the forecast period covered in the report?

The Polymyositis Epidemiology report for the 7MM covers the forecast period from 2024 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.

2. Out of all EU4 countries and the UK, which country had the highest population of Polymyositis cases in 2023?

The highest cases of Polymyositis was found in the Germany among EU4 and the UK in 2023.

3. How is epidemiological data collected and analyzed for forecasting purposes?

Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.

4. Out of all 7MM countries, which country had the highest population of Polymyositis cases in 2023?

The highest cases of Polymyositis were found in the US among the 7MM in 2023.